



ABOUT THOR

The THOR Network Foundation is a US based 501(c)(3) public charity organization. It is an international multidisciplinary network of civilian and military providers ranging from first responders and medics to physicians from multiple disciplines, as well as basic scientists, bioengineers, and clinical trialists. The international influence of THOR is evidenced by our membership of over 1,000 subject matter experts from over 31 countries from all continents (except Antarctica). See www.thornetwork.com for more information about the THOR Network Foundation and the THOR Research Institute.

The Annual THOR Symposium is an invitation-only meeting with key opinion leaders from civilian and military medicine that has changed practice in several disciplines. Examples include the widespread increased use of whole blood and cold stored platelets internationally in both civilian and military practice by collaborating with the AABB and blood suppliers around the world. Medics and civilian prehospital providers are an essential aspect of the Network and contribute significantly to the evidence and experience-based cutting-edge clinical practice and science presented at our annual conference.

The Regional THOR Conference is open invite to local experts and will be attended by a large number of THOR leaders and subject matter experts to compliment the speakers from the region. The regional conference will also have a healthy balance of prehospital providers and translational scientists to provide a multidisciplinary group of presenters and attendees.

OUR MISSION: To develop and implement best practices for prehospital damage control resuscitation in trauma care through to the completion of the acute phase of hemorrhagic shock resuscitation at higher echelons of care. The THOR Network will execute this mission through a multidisciplinary collaborative approach to research, education, training, and advocacy.

OUR VISION: To improve outcomes from trauma-induced hemorrhagic shock by optimizing the acute phase of resuscitation.

ABOUT THE THOR CONFERENCE

There are often many representatives from the US Department of Defense including:

- Defense Health Agency
- Program Executive Office - Operational Medicine (PEO OPMED). Previously named USAMMDA
- US Army Futures Command
- Combat Casualty Care Research Program
- US Army Institute of Surgical Research
- US Navy Research Medical Unit
- Committee on Tactical Combat Casualty Care
- Special Operations Command (SOCOM)
- DARPA

Health and Human Services (HHS) representatives often include leadership from:

- BARDA
- NIH
- FDA/CBER

There will also be representation from collaborating societies or associations:

- AABB - Association for the Advancement of Blood & Biotherapies
- SOMA – Special Operations Medical Association
- ISBT – International Society of Blood Transfusion Shock Society
- AAST – American Association for the Surgery of Trauma
- ACS CoT - American College of Surgeons Committee on Trauma
- South Texas Regional Advisory Council

Leadership from blood suppliers from around the world will often include representation from:

- American Red Cross
- New York Blood Center
- Vitalant
- South Texas Blood and Tissue Center
- Magen David Adom of Israel
- NHS Blood and Transplant of the United Kingdom
- French National Blood Service (EFS)
- Canadian Blood Services
- Norwegian Blood Service
- Japan Red Cross Society

Military Medical Leadership often includes representatives from military medical leadership including special operations forces from:

- | | | |
|------------------|---------------|------------------|
| ● Australia | ● Israel | ● Sweden |
| ● Canada | ● Italy | ● Singapore |
| ● Czech Republic | ● Japan | ● Ukraine |
| ● Finland | ● Netherlands | ● United Kingdom |
| ● France | ● Norway | ● United States |
| | ● Spain | ● Taiwan |

Annual THOR Symposium in Collaboration with the Irish Blood Transfusion Service

Annually the agenda includes presentations that focus on prehospital care, current epidemiology of life-threatening bleeding, and clinical trial results informing best practices for patients with trauma-induced hemorrhagic shock from the prehospital phase of care to ICU care. Practical techniques to reduce bleeding are also emphasized by leaders in prehospital and emergency care. Optimal methods of training and education are always a focus to expedite the implementation and dissemination of remote damage control principles. In addition, the conference agenda includes basic science on the pathophysiology of hemorrhagic shock that can inform the development of new blood products, diagnostics, and therapeutics to improve outcomes.

Our focus includes accelerating diagnostic assay and therapeutic product development that targets identifying and mitigating cellular injury resulting from hypoperfusion and the downstream effects of hemorrhagic shock on the endothelium, immune system, and hemostasis. Our goals also include examining the common biology seen in multiple etiologies of hemorrhagic shock that can allow for the use of novel therapeutic agents to improve outcomes for all patients with severe bleeding. The development of assays that accurately and rapidly assess shock physiology to include endothelial, immune, and hemostatic functions are required to achieve precision resuscitation care. THOR will continue to engage with bioengineering experts to facilitate collaboration with clinicians and scientists

to develop next generation assays that can assist with the indications for therapies and ultimately improve outcomes.

At the Annual Symposium in Ireland, to facilitate investment in next generation assays and therapeutics there will first be a session focused on the science of potential assays and therapeutics for hemorrhagic shock. Following this session there will be a think tank session led by Ivan Yates (Former Irish politician, businessman, and broadcaster) with a panel of subject matter experts to include venture capital experts in the biomedical field. The goal of this think tank session is to develop a pathway for the development and funding of next generation assays and therapeutics. The regional meeting in Italy will also focus on optimizing the pathway to device approval or product licensing in the field of hemorrhagic shock of all etiologies. The sessions at this meeting will also allow for input from biomedical industries and venture capital experts in biomedical science.

Biomedical industries and venture capital experts need to inform the scientists and government funding agencies what they value in the development pathway of a new product to optimize the chances that one in development not only gets approved but is also implemented widely in both civilian and military markets. We are inviting venture capital leaders in the biomedical field to sponsor the THOR Network Annual Symposium in Ireland and the Regional Conference in Italy to increase visibility of the potential for the development of diagnostics and therapeutics for hemorrhagic shock for all etiologies to include trauma, surgical, postpartum, and gastrointestinal bleeding. There is a very large market for improved diagnostics and therapeutics for severe bleeding that has not been capitalized upon. Venture capital input is needed not only for what gets developed but also how it is done efficiently, rapidly, and effectively.

While the focus of THOR is traumatic bleeding, lessons learned or applications of hemostatic resuscitation in other disciplines such as severe bleeding from post-partum hemorrhage, gastrointestinal bleeding, acute radiation syndrome, and other medical and surgical causes of bleeding are often presented and discussed.

Regional THOR-CNS meeting in Rome, Nov 9-11, 2026

Conference Title: State of the Science in Resuscitation Medicine for Severe Traumatic Bleeding: Clinical, Logistical, and Regulatory Insights with a Focus on European Perspectives.

Severe traumatic bleeding remains one of the leading and most preventable causes of death globally, underscoring the urgent need for coordinated progress across basic science, clinical practice, system organization, and regulatory frameworks. This international symposium convenes leaders in trauma care, transfusion medicine, military medicine, health systems organization, and regulatory policy to assess the current state of the science in resuscitation medicine and to define a shared European vision for the future of trauma and haemorrhage care.

The programme spans the full translational continuum—from the pathophysiology of trauma-induced coagulopathy and haemorrhagic shock to emerging diagnostics, advanced haemostatic therapies, and precision transfusion strategies. In parallel, it addresses system-level implementation challenges, including trauma system organization, prehospital blood programmes, and workforce training, logistics, and data infrastructure. Civilian and military experiences are deliberately integrated to highlight transferable lessons and to strengthen preparedness for both daily trauma care and large-scale emergencies.

A strong emphasis is placed on European collaboration and regulatory alignment, particularly in light of the new European Regulation on Substances of Human Origin (SoHO). The programme also recognizes the essential roles of patients, voluntary blood donor associations, and public trust in sustaining resilient transfusion systems. By connecting mechanistic insights, clinical evidence, operational experience, and regulatory perspectives, the conference aims to accelerate innovation,

enhance system readiness, and ensure that advances in resuscitation and transfusion medicine translate into improved survival and equitable access to care across Europe and beyond.

For additional information about the THOR Network Foundation Contact:

Kara O'Connor, Director, THOR Network Relations, Koconnor@thornetwork.com

Sincerely,

Philip C. Spinella, MD, FCCM

President, THOR Network Foundation
Co-Director, THOR Research Institute
Professor, Department of Surgery
Professor, Critical Care Medicine
University of Pittsburgh, Pittsburgh, PA.

Elon Glassberg, MD, MHA, MBA

Vice President, THOR Network Foundation
Immediate past Surgeon General, Israel Defense Forces
Prof. of Surgery- Bar Ilan University (Israel)
Adjunct Professor of Surgery- USUHS (Bethesda, MD)
Board Certified in Health Care Management